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ABSTRACT
Age is the highest risk factor for some of the most prevalent human
diseases, including cancer. Telomere shortening is thought to play a
central role in the aging process in humans. The link between
telomeres and aging is highlighted by the fact that genetic diseases
causing telomerase deficiency are associated with premature aging
and increased risk of cancer. For the last two decades, this link has
been mostly investigated using mice that have long telomeres.
However, zebrafish has recently emerged as a powerful and
complementary model system to study telomere biology. Zebrafish
possess human-like short telomeres that progressively decline with
age, reaching lengths in old age that are observed when telomerase
is mutated. The extensive characterization of its well-conserved
molecular and cellular physiology makes this vertebrate an excellent
model to unravel the underlying relationship between telomere
shortening, tissue regeneration, aging and disease. In this Review,
we explore the advantages of using zebrafish in telomere research
and discuss the primary discoveries made in this model that have
contributed to expanding our knowledge of how telomere attrition
contributes to cellular senescence, organ dysfunction and disease.
KEY WORDS: Aging, Cancer, Disease, Telomerase, Telomeres,
Zebrafish
Introduction
The ends of eukaryotic chromosomes are capped by telomeres,
which are composed of repeated hexanucleotide DNA sequences
[(TTAGGG)n] averaging from 5 to 15 kb in humans (Moyzis
et al., 1988) and an associated protein complex known as ‘shelterin’
(de Lange, 2005). Telomeres are crucial for genome stability:
they prevent chromosome ends from engaging in illegitimate
repair and ensure their maintenance by recruiting the enzyme
telomerase, a reverse transcriptase that elongates telomeres (de
Lange, 2005).
In humans, telomerase is found active particularly in germ cells
and certain adult stem cells, and can be transiently upregulated by
cells of the immune system (Hiyama and Hiyama, 2007; Hodes
et al., 2002; Kim et al., 1994; Weng et al., 1997). In contrast, the
majority of differentiated somatic cells have no detectable levels of
telomerase (Kim et al., 1994). Consequently, telomeres shorten with
each round of cell division and with aging (Harley et al., 1990). Cell
turnover, however, is not sufficient to predict how fast tissues lose
telomere sequences (Daniali et al., 2013). Accordingly, alternative
mechanisms have been proposed to contribute to telomere
shortening, including post-replicative processing by exonucleases
(such as Apollo and Exo1) (Chai et al., 2006; Wu et al., 2012) and
oxidative stress (Oikawa et al., 2001; Passos et al., 2007; Saretzki
et al., 2003).
Telomeres that have been shortened to critical lengths are
recognized as DNA double-strand breaks (DSBs) and trigger
mechanisms constituting DNA-damage responses (DDRs) that
culminate in a specific type of cell-cycle arrest, designated by
Hayflick as ‘replicative senescence’ (d’Adda di Fagagna et al.,
2003; Hayflick and Moorhead, 1961; Olovnikov, 1996; van
Steensel et al., 1998). Senescence induced by short telomeres
can lead to both favourable and deleterious consequences. On the
positive side, this phenomenon can avert the indefinite proliferation
of malignant tumour cells, and thus prevent the development of
cancer (Kim et al., 1994). On the negative side, it limits the function
of stem cells that are necessary for tissue regeneration, potentially
contributing to the loss of tissue homeostasis observed in aging
(Aubert and Lansdorp, 2008; Campisi, 2014).
A prominent role for telomeres in aging has been supported
by studies showing that mutations in genes crucial for telomere
maintenance cause degenerative disorders that result in premature-
aging symptoms (progeria-type diseases dubbed ‘telomeropathies’)
(Armanios and Blackburn, 2012; Carrero et al., 2016). An example
of a multisystem disorder caused by defective telomere maintenance
is dyskeratosis congenita (DC). Individuals with DC often carry
mutations in TERT and TERC, which encode the catalytic and RNA
subunits of telomerase, respectively. Other genes that have been
implicated in the disease include TIN2 (TERF1-interacting nuclear
factor 2), which encodes a component of shelterin, and genes
involved in the biogenesis and trafficking of telomerase, including
DKC1 (dyskerin; dyskeratosis congenita 1), NOP10 (nucleolar
protein 10) and TCAB1 (telomerase Cajal body protein 1)
(Armanios et al., 2005; Heiss et al., 1998; Marrone et al.,
2007; Trahan et al., 2010; Vulliamy et al., 2001; Vulliamy and
Dokal, 2008; Walne et al., 2007; Zhong et al., 2011). DC
individuals have much shorter telomeres than their
unaffected relatives and die prematurely, presenting characteristic
dysfunctional phenotypes in their first decade of life, including
nail dystrophy, oral leukopathies and hyperpigmentation of the
skin (Kirwan and Dokal, 2009). Other characteristics reminiscent
of aging can develop later on, such as premature greying of the hair,
hair loss (alopecia), a condition affecting teeth known as
taurodontism, osteoporosis and cancer (Armanios, 2009). The
majority of affected individuals die from bone-marrow failure due to
an impaired renewal capability of hematopoietic stem cells (HSCs)
(Basel-Vanagaite et al., 2008; Jacobs et al., 1984). Hoyeraal-
Hreidersson syndrome (HHS) is a rare and severe variant of
DC. In addition to DC symptoms, HHS is clinically characterized
by cerebellar hypoplasia and microcephaly (Aalfs et al.,
1995). Other exceptionally rare variations of DC include Revesz
syndrome and Coats plus syndrome (Ramasubramanian and
Shields, 2012; Scheinfeld et al., 2007). Interestingly, these
disorders exhibit a pattern of genetic anticipation, in which later
generations of carriers have shorter telomeres and suffer from an
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earlier onset of disease with aggravated symptoms (Holohan et al.,
2014). TERT heterozygote carriers can express some form of DC
and even wild-type children inherit shorter telomeres (than average)
from their parents (Chiang et al., 2010). The reason why these
children would inherit and maintain shorter telomeres in the
presence of telomerase remains unclear.
To complement studies of humans with DC, late-generation
telomerase-knockout mice (obtained by incrossing telomerase
mutants for several generations, typically three or four) have been
used. These mice provide a crucial laboratory tool to assess how
telomere shortening promotes aging (Blasco et al., 1997; Rudolph
et al., 1999). However, these mice fail to demonstrate full
penetrance of DC symptoms, possibly owing to the fundamental
differences in telomere length, cell immortalization and entry
into senescence that distinguish mouse cells from human cells
(Wright and Shay, 2000). This has fuelled the characterization of
alternative telomerase-deficient vertebrate animals to more
effectively bridge the gap between model organisms and humans
in the study of telomere biology and aging. This Review offers
a synthesis of the primary discoveries made in zebrafish models
that have furthered our understanding of how short telomeres or
the absence of telomerase can contribute to aging (from cellular
senescence to tissue dysfunction) and disease (DC and cancer). We
discuss the similarities between zebrafish telomere biology and
mammalian (mouse and human) telomere biology. Finally, we raise
awareness of questions that remain unsolved in the telomere-aging-
disease triangle, in particular how this interplay is mediated at the
molecular level and highlight the advantageous features of zebrafish
– such as rapid development and ease of drug screening – that could
help to address these questions in the near future.
Zebrafish telomeres in aging –why study them?
Most short-lived rodent species die before telomeres reach the
lengths found in human senescent cells (Flores et al., 2008; Gomes
et al., 2011; Harley et al., 1990). The common lab mouse, which has
been the primary model to date for studying how telomere
shortening impacts organismal homeostasis, has telomeres
ranging from 20-150 kb in length (Kipling and Cooke, 1990).
Telomeres in mice are thus four- to ten-times bigger than telomeres
in humans, whose average telomeres generally range from 5-15 kb
(Moyzis et al., 1988; Wright and Shay, 2000). Strikingly,
telomerase-deficient lab mice are viable through several
generations of incrossing (mating of animals that are homozygous
for the TERT or TERC loci). Previous studies showed that only later
generations displayed severe disease phenotypes (e.g. premature
death, infertility, intestinal atrophy, bone-marrow failure) (Blasco
et al., 1997; Lee et al., 1998). This contrasts with the immediate
(first generation) tissue-dysfunction phenotypes and decreased
lifespan of humans carrying mutations in telomerase genes. One
single study found, however, that the first generation (G1) of inbred
Terc−/−mice already exhibited reductions in medium and maximum
survival (García-Cao et al., 2006). It remains unclear whether the
discrepancies found between these findings and those reported in
earlier studies involving telomerase-knockout mice are related to
strain differences.
Thus, there is a high demand for the development of alternative
vertebrate models that, like humans, require telomerase for normal
lifespan and tissue homeostasis. In this regard, two short-lived fish
species with human-like telomeres have emerged as promising
complementary vertebrate models: zebrafish (5-15 kb telomeres)
and the GRZ killifish strain (6-8 kb telomeres) (Alcaraz-Pérez et al.,
2014; Anchelin et al., 2013; Bednarek et al., 2015; Carneiro et al.,
2016; Harel et al., 2015; Henriques et al., 2013; Imamura et al.,
2008; Kim et al., 2016).
The GRZ killifish inbred strain offers a great advantage in studies
of aging: of all vertebrate models bred in laboratory conditions, it has
the shortest natural lifespan, with a maximum of 6 months (Harel
et al., 2015). However, unlike in humans, telomere shortening with
age is not observed in the GRZ strain (Hartmann et al., 2009). In
addition, although telomerase deficiency in killifish causes premature
tissue dysfunction, including gut villi atrophy, infertility, loss of
blood cellularity and epithelial adenomatous changes, it appears not
to influence the lifespan of the organism, nor embryo telomere length,
in the first generation (Harel et al., 2015). Crucially, it remains to be
shown whether the tissue degeneration observed in telomerase
killifish mutants is a consequence of telomere shortening during
adulthood. Future studies should also evaluate the possibility of using
other killifish strains, such as the wild-derived strain MZM-0403 (a
short-lived strain with human-like telomeres that shorten with age), as
alternative models for telomere research (Hartmann et al., 2009).
The use of zebrafish, which has a maximum lifespan of
43 months (Carneiro et al., 2016), as a model to study the effects
of telomerase deficiency and telomere shortening in aging, cancer
and regeneration has been growing at a fast pace in the past decade
(Anchelin et al., 2013; Bednarek et al., 2015; Carneiro et al., 2016;
Henriques et al., 2013; Imamura et al., 2008; Wang et al., 2014).
The functional domains of zebrafish telomerase are highly similar to
their human counterparts [N-terminus, telomerase RNA (TR)-
binding site and reverse transcriptase (RT) motifs] (Imamura et al.,
2008; Lau et al., 2008). As in humans, the zebrafish telomerase
promoter is activated by Myc and NF-κB (Lau et al., 2008).
Telomerase expression, although detected in most zebrafish tissues,
declines with age (Anchelin et al., 2011; Lau et al., 2008).
Consequently, as in humans, telomeres also shorten significantly
over time in tissues such as blood and muscle (Anchelin et al., 2011;
Carneiro et al., 2016). Three interesting aspects of telomere
shortening in zebrafish further substantiate that this organism is
an effective model to study human telomere biology:
1. As reported for humans (Daniali et al., 2013), telomere
shortening occurs both in high-turnover (e.g. gut) and low-
turnover (e.g. muscle) organs in zebrafish, regardless of
differences in proliferation rates (Carneiro et al., 2016). What
determines shortening in tissues with lower proliferation rates is
unknown, but causality between higher reactive oxygen
species (ROS) levels and telomere shortening remains to be
tested. ROS are known to cause genotoxic damage particularly
in G-rich DNA regions, including telomeres (Henle et al.,
1999; Oikawa et al., 2001), which could result in their attrition.
2. In zebrafish gut and muscle tissue, pronounced telomere
erosion occurs within the first 1.5 years, after which no
significant shortening can be detected. In humans, a similar
trend of accentuated shortening during puberty followed by
stabilization in length at later ages has been described (Aubert
et al., 2012; Rufer et al., 1999; Sidorov et al., 2009) and could
reflect the elimination of cells with extremely short telomeres,
possibly via apoptosis.
3. The accumulation of short telomeres and of damage at
telomeres over time in zebrafish anticipates the onset of
tissue-specific phenotypes of aging, such as intestinal
inflammation, and of aging-associated diseases, such as
cachexia and, surprisingly, cancer (contrary to several
oncogene-driven telomerase-knockout models) (Carneiro
et al., 2016) (Fig. 1).
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Altogether, these studies strongly support the hypothesis that,
similarly to in humans but in contrast to in GRZ killifish, telomere
shortening acts as a major contributor to the increase in DNA
damage, tissue dysfunction and disease observed in zebrafish aging
(Fig. 1). Accordingly, many larval and adult models have emerged
to directly explore how these variables are interconnected. These are
reviewed in the next sections and some provocative questions of
where telomere research in zebrafish could lead us are raised.
A model of vertebrate accelerated aging: the telomerase
mutant zebrafish
The crucial need to evaluate how telomere shortening regulates
tissue homeostasis in vertebrates with human-like telomeres has
led to efforts to characterize the telomerase-deficient zebrafish
strain terthu3430/hu3430 (Anchelin et al., 2013; Henriques et al., 2013)
(Table 1). First-generation terthu3430/hu3430 zebrafish, hereafter
referred to as tert−/−, have shorter telomeres than wild-type
zebrafish and die prematurely (Anchelin et al., 2013; Henriques
et al., 2013). tert−/− zebrafish develop several degenerative
phenotypes. Homeostasis is disrupted in tert−/− highly
proliferative tissues (e.g. testis and gut), resulting in infertility,
gastrointestinal atrophy and inflammation. Low-proliferation
tissues, such as muscle and eye, also display dysfunctional
phenotypes, including sarcopenia (muscle) and retinal atrophy
(eye) (Anchelin et al., 2013; Henriques et al., 2013). Strikingly, the
majority of these tissue-dysfunction events tightly phenocopy those
that occur during natural zebrafish aging (Carneiro et al., 2016). In
addition, tert−/− zebrafish exhibit an accelerated onset of several
age-related diseases, such as cachexia, gas-bladder infection and
cancer (discussed below). These studies substantiate that the
telomerase mutant zebrafish, an organism with artificially
shortened telomeres, is an effective model to study the responses
elicited by natural telomere erosion in physiological aging.
As in mammals, telomerase dosage seems to be a crucial factor
for zebrafish homeostasis. This is underscored by the observation
that more than 50% of a tert−/− incross progeny (second-generation
tert−/− mutants or G2 tert−/−) die within the first week of life
(Anchelin et al., 2013), a phenomenon that can be partially rescued
by restoring telomerase activity (Anchelin et al., 2013). The severity
of developmental defects found in G2 tert−/− zebrafish is
proportional to the amount of critically short telomeres, measured
as ‘telomere free-ends’ (Anchelin et al., 2013). Thus, telomerase
deficiency causes a disease anticipation phenomenon in zebrafish,
reproducing what is typically observed in human telomeropathies.
Further supporting a vital role for telomeres in zebrafish
homeostasis, mutants for the telomere repeat binding factor 2 (Terf2
in mammals; Terfa in zebrafish), terfahi3678/hi3678, are embryonically
lethal (Table 1). In addition, these embryos demonstrate premature
retinal neurodegeneration and senescence in the brain and spinal cord
(Kishi et al., 2008).Adult terfa heterozygotes, althoughviable, exhibit
signs of premature retinal degeneration and have a shorter lifespan
compared with wild type (Kishi et al., 2008) (Table 1).
Many exciting questions follow these ground-breaking studies
using adult zebrafish models, perhaps the most pressing being
whether telomerase-activating therapeutics can delay zebrafish aging.
Single telomerase gene therapy treatments using recombinant non-
integrative adeno-associated viruses (AAVs) seem to be sufficient to
delay the incidence of aging-associated pathologies and extend wild-
type mouse lifespan, an animal with comparatively long telomeres
(Bernardes de Jesus et al., 2012). Is whole-body telomerase
overexpression sufficient to delay aging in zebrafish, an animal
with human-like telomeres? If targeted to specific tissues where
telomeres shorten over time, is telomerase overexpression sufficient to
prevent local and systemic damage in aging? Is there an optimal
therapeutic time window before age-associated defects become
irreversible? Answers to these questions will provide crucial clues
for the development of telomerase-based rejuvenation therapies.
The complex interplay between telomeres, telomerase and
cancer
Telomere shortening commits cells to growth arrest after a certain
number of divisions – a mechanism that acts as a robust suppressor
of tumour growth (Harley et al., 1990; Hayflick and Moorhead,
1961). Cells with short telomeres, however, can find ways to bypass
replicative senescence, such as acquiring a mutation in the cell-cycle
regulator p53 that favours continuing proliferation (Chin et al.,
1999). Resumed proliferation ramps up chromosomal instability
(‘crisis’), resulting in massive death mediated by mitotic telomere
deprotection –where telomeres can no longer be distinguished from
DNA damage – and chromosome fusions (Chin et al., 1999;
Time (years)
Muscle
GutTestis
Head kidney
Local effects
Systemic effects
Sarcopenia
Inflammation
Cancer
Cachexia
Infertility
Telomere size
Long Short
Systemic signals of
short-telomere
dysfunction
0.3 2
Key
Fig. 1. Telomeres shorten at different rates, anticipating local and systemic tissue dysfunction in zebrafish aging. Telomeres shorten naturally over time in
specific zebrafish organs, such as the gut and muscle (but not testes), regardless of differences in proliferation rates. This shortening, together with the
accumulation of local telomere damage, precludes the onset of tissue-dysfunction events in aging, including intestinal inflammation and sarcopenia. Critically
short telomeres in the gut and muscle might prove to be sufficient in disrupting homeostasis in unrelated tissues, where telomeres do not shorten, by generating
systemic signals (purple) of dysfunction that create a ‘disease-permissive’ environment.
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Hayashi et al., 2015). Such events favour the selection of mutations
that promote activation of telomere maintenance programs that
facilitate sustained proliferation – 90% of human cancers achieve
this by reactivating telomerase (Kim et al., 1994; Meyerson et al.,
1997; Shay and Bacchetti, 1997). Thus, although telomere
shortening might have evolved to keep cancer at bay, it also
Table 1. Zebrafish models for telomere and telomerase research
Zebrafish model
Effects on telomerase activity/
telomere length Tissues affected Key mutant phenotypes References
tert hu3430/hu3430 No telomerase activity/shorter
telomeres
Testis, gut,
muscle, eye, fat
layer, swim
bladder
1st generation:
• Shorter lifespan – average 11 months vs
31 months in wild-type zebrafish
• Shorter telomeres in several tissues
• Premature tissue aging: infertility, gastrointestinal
atrophy and inflammation, sarcopenia and retinal
atrophy, thinning of subcutaneous fat layer
• Premature aging diseases: cachexia, swim-
bladder infection and cancer
2nd generation:
• Embryonic lethal (average lifespan 1 day);
develops with multiple malformations
• Very short telomeres, multiple telomeric signals
and chromosome fusions.
Henriques et al., 2013;
Anchelin et al., 2013;
Carneiro et al., 2016
terfahi3678/hi3678 ND Brain, spinal cord,
eye
• Embryonic lethal
• High SA-β-gal activity in the brain and spinal cord
• Retina degeneration
• Telomere fusions and chromosomal fragility
• High levels of ROS in the neural tube and cell
death
Kishi et al., 2008
terfahi3678/+ ND Eye • Shorter lifespan (males) – average ca. 28 months
vs WT ca. 38 months
• Retinal degeneration
Kishi et al., 2008
terthu3430/hu3430
tp53M214K/M214K
No telomerase activity/shorter
telomeres
Testes, gut • Longer lifespan (87% tert−/−tp53−/− alive at
12 months vs 0% of tert−/−)
• Increased proliferation and apoptosis in gut and
testes, compared to tert−/− levels
• Suppression of tert−/− gut-villi length defects
• Fewer developmental malformations and
significant lifespan rescue in G2 tert−/− larvae
Henriques et al., 2013;
Anchelin et al., 2013
nop10hi2578/hi257 Telomerase activity has not
been characterised/no
difference in telomere length
Blood • Embryonic lethal by 5 dpf
• Failure of 18S rRNA processing, resulting in a
collapse of the 40S small ribosomal subunit.
• No telomere shortening by 4 dpf.
• Erythrocyte loss.
• p53-dependent apoptosis of HSC.
Pereboom et al., 2011
nop10hi2578/hi2578
tp53M214K/M214K
Telomerase activity has not
been characterised/no
difference in telomere length
Blood • Introduction of the tp53M214K/ M214K alleles to the
nop10−/−mutant is enough for HSC development
to proceed
Pereboom et al., 2011.
Terc MO No telomerase activity/no
difference in telomere length
Blood • Normal emergence of HSCs, with an alteration of
cell fate
• Change in developmental myelopoiesis, through
the regulation of the master myeloid and erythroid
transcription factors spi1 and gata1
• Strong neutropenia and monocytopenia
• Phenotypes are independent of telomerase
activity and telomere length
Alcaraz-Perez et al.,
2014;
Tert MO Decreased telomerase activity/
no difference in telomere
length
Blood • Hypochromic anemia
• Abnormal differentiation and apoptosis of
hematopoietic stem and/or progenitor cells
• The apoptotic and cytopenic phenotypes are
p53- and Bcl-2-dependent
• The hematopoietic defects are restored upon
zebrafish or human TERT expression
• Absence of telomere length alterations
Imamura et al., 2008).
Dkc1 MO Normal telomerase activity/no
difference in telomere length
Blood • HSC failure
• Increased expression of p53
• Defective ribosomal biogenesis
• Hematopoietic defects are rescued by p53
inhibition
• No detectable changes in telomerase function
Zhang et al., 2012
dpf, days post-fertilization; HSC, hematopoietic stem cell; MO, morpholino; ND, not defined; ROS, reactive oxygen species; WT, wild type.
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promotes the selection of unstable cells that can effectively bypass
tumour-suppressor checkpoints (Artandi et al., 2000).
Surprisingly, telomerase activity is not rate-limiting for zebrafish
tumorigenesis: tert−/− mutants develop spontaneous tumours at a
similar frequency as wild-type animals (Carneiro et al., 2016).
Similar to other aging-related diseases, cancer emerges prematurely in
tert−/− zebrafish (as early as 4 months) bearing the characteristics of
normal old age. Similar to wild-type zebrafish, tert−/− cancer has an
8% incidence, consists mainly of germ cell tumours, hematopoietic
neoplasias and intestinal adenocarcinomas, and has a 40% invasion
rate (Carneiro et al., 2016). It is not obvious how this reconciles with
the scenario in mice, in which the effects of telomerase deficiency in
tumorigenesis vary according to genetic context and p53 status
(Artandi, 2002; Artandi et al., 2000; Artandi and DePinho, 2000).
Indeed, late-generation telomerase-knockout mice have either higher
cancer rates (Artandi et al., 2000; Blanco et al., 2007; Rudolph et al.,
1999), lower cancer rates (sometimes with more initiation events)
(Farazi et al., 2003; González-Suárez et al., 2000; Greenberg et al.,
1999; Hu et al., 2012; Rudolph et al., 2001) or unaltered cancer rates
(Argilla et al., 2004). These studies in mice indicate the need for a
deepened understanding of how telomerase knockout affects cancer
incidence, and the study of different oncogene-expressing zebrafish
transgenic lines could meet this need.
Even if tumours arise in short-telomere tert−/− zebrafish cells,
their growth and progression will expectedly require the activation
of a telomere-maintenance mechanism. The (yet undemonstrated)
explanation is that tert−/− zebrafish tumours are efficient in
engaging mechanisms of alternative lengthening of telomeres
(ALT) (Bryan et al., 1997). Several studies support that ALT is
achieved by homologous recombination (HR) mechanisms at
telomeres. Consistently, DNA tags inserted into telomeres are
copied between chromosome ends in ALT cell lines, which are
telomerase-negative, but not in telomerase-positive cells (Dunham
et al., 2000). ALT is thought to occur in approximately 10% of
human cancers (Shay and Bacchetti, 1997) and is more prevalent in
tumours of mesenchymal origin (Lafferty-Whyte et al., 2009).
Because zebrafish cancer rates are not affected by the absence of
telomerase, it is tempting to speculate that ALT could constitute a
central pathway in telomere maintenance in tumorigenesis. In the
context of tert+ tumors, telomerase might simply provide a more
stable (rather than a more common) solution to promote genome
stability and outcompete ALT-based mechanisms. Consistent with
this idea, recent studies show that ALT telomeres promote genome
instability by recombining chromosome ends with interstitial
regions (Marzec et al., 2015).
CharacterizingALT is therefore of crucial importance for the study
of telomere dynamics in zebrafish cancer. Because the zebrafish
genome lacks a clear promyelocytic leukemia (PML) gene (Veinotte
et al., 2014), it is impossible to assess the presence ofALT by probing
for characteristic complexes of promyelocytic leukemia nuclear
bodies associated with telomeres, known as APBs (ALT-associated
PML bodies). ALT tumours are nevertheless characterized by other
features, including heterogeneous telomere length (with very short
and very long sequences) (Bryan et al., 1997), and the presence of
extrachromosomal telomeric DNA that forms double-stranded
(t-circles) (Wang et al., 2004) and single-stranded (C- or G-circles)
(Henson et al., 2009) circles. In addition, several recombination
proteins are necessary for telomere maintenance in ALT cells,
including the MRN complex (MRE11, RAD50 and NBS1) (Jiang
et al., 2005; Zhong et al., 2007), subunits of the SMC5/6 (structural
maintenance of chromosomes 5/6) complex (Potts and Yu,
2007), FEN1 (flap structure-specific endonuclease 1) (Saharia and
Stewart, 2009), MUS81 (structure-specific endonuclease subunit)
(Zeng et al., 2009) and FANCD2 (Fanconi anemia group D2) (Fan
et al., 2009). Looking at a combination of these features will help
determine whether ALT is a prevalent mechanism in zebrafish
tumorigenesis. This could be of consequence if we are to consider
the potential use of zebrafish for performing chemical screens for
anti-ALT therapies with possible relevance to certain human cancers.
Zebrafish models for dyskeratosis congenita
As detailed earlier, DC is a bone-marrow-failure disorder
characterized by shortened telomeres, defective stem cell
maintenance and highly heterogeneous phenotypes affecting
predominantly tissues that require high rates of turnover, such as
skin and lung epithelium and bone marrow (Kirwan and Dokal,
2009). Although the majority of individuals with DC die from bone-
marrow failure, the associated increased risk of cancer also
contributes to DC mortality (Alter et al., 2009).
All mutations identified to date in DC individuals are found in
components of telomerase and in genes that are required for its
biogenesis, or in telomere-stabilizing elements (Vulliamy and Dokal,
2008). All of these mutations lead to defects in telomere biology and
affect the renewal capabilities of HSCs (Brümmendorf and
Balabanov, 2006; Drummond et al., 2007). Mutations in telomerase
genes (TERC and TERT) are autosomal dominant owing to
telomerase haploinsufficiency and show disease anticipation
associated with progressive telomere shortening (Vulliamy and
Dokal, 2008). G1 tert−/− zebrafish have premature aging
symptoms, with the most apparent phenotype being the sharp
decline in the mean life expectancy (Anchelin et al., 2013; Henriques
et al., 2013). Interestingly, tert+/− zebrafish also have reduced
longevity compared with wild type, while G2 tert−/− fish die before
the secondweekof life, suggesting that telomere length is essential for
zebrafish lifespan (Anchelin et al., 2013) (Table 1). Thus, as in
humans, telomerase haploinsufficiency in zebrafish leads to telomere
shortening and reduced longevity, despite the presence of telomerase.
Moreover, the decrease in lifespan in zebrafish is proportional to the
degree of telomere shortening (Anchelin et al., 2013).
Surprisingly, mutations affecting TERC (such as G58A) are not
associated with impaired telomerase activity in vitro (Chen and
Greider, 2003), despite leading to particularly severe disease in humans
(VulliamyandDokal, 2008; Chen andGreider, 2003). Various lines of
evidence have shown that the cancer-promoting activity of TERC
seems to be independent of in vitro telomerase activity, consistent with
the hypothesis that TERC might play a non-canonical role in DC
pathogenesis. For example, telomerase can promote tumorigenesis in
mice independently of net telomere elongation (Blasco et al., 1996).
Moreover, several groups have shown that mice with transgenic
expression of TERT have a higher susceptibility to develop tumours in
the absence of telomere length differences (Artandi et al., 2002; Canela
et al., 2004; González-Suárez et al., 2001) and that this effect is
dependent on the presence of TERC (Cayuela et al., 2005). These
observations, together with the ability of TERC to specifically bind to
2198 sites in the human genome (Chu et al., 2011), have led to the
hypothesis that TERChas non-canonical cellular functions, potentially
involving the regulation of gene expression.
Non-canonical roles for telomerase have also been described in
zebrafish. Genetic depletion of terc in zebrafish embryos [using
antisense morpholino (MO)-mediated knockdown technology]
resulted in dramatic loss of neutrophils and monocytes independent
of telomerase activity or telomere shortening (Alcaraz-Pérez et al.,
2014) (Table 1). Similarly, a study identified a role for tert in
promoting the development of hematopoietic cells in zebrafish,
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through amechanism that is independent of its telomerase activityand
function in telomere lengthening (Imamura et al., 2008). The authors
showed that tert morphant zebrafish embryos exhibit abnormal
differentiation and apoptosis of hematopoietic stem and/or progenitor
cells, subsequently leading to the circulation of immature blood cells
and anaemia without any obvious telomere shortening (Imamura
et al., 2008) (Table 1). This mirrors the low number of circulating
blood cells – including red blood cells, white blood cells and platelets
– observed in human DC (Kirwan and Dokal, 2009).
DC also encompasses genes involved in telomerase biogenesis.
Dyskerin (DKC1), a member of the H/ACA ribonucleoprotein (RNP)
complex, was the first gene discovered to be responsible for the X-
linked severe form of DC. DKC1 is involved in telomerase function
through its RNA subunit, which contains an H/ACA RNA motif, and
integrity of this motif is essential for assembly and stability of the
human telomerase RNP (Vulliamy et al., 2006). Knockdown of dkc1
revealed a role in zebrafish hematopoiesis (Zhang et al., 2012).
Downregulation of dkc1 results in HSC failure, increased p53
expression and defective ribosomal biogenesis, all without detectable
changes in telomerase activity (Zhang et al., 2012) (Table 1).Mutations
in two other H/ACA RNP complex genes, NHP2 (Vulliamy et al.,
2008) andNOP10 (Walne et al., 2007), have also been reported in DC.
In line with the previously discussed zebrafish DC models, nop10
mutant embryos also fail to form HSCs and, again, these mutants
display no telomere shortening (Pereboom et al., 2011) (Table 1).
In all four of these zebrafish models, telomere lengths are not
significantly altered, supporting a model for DC pathogenesis
where mutations in TERC, TERT, DKC1 and NOP10 contribute to
bone-marrow failure through a telomere-lengthening- independent
mechanism. In line with these observations, some of the previously
reported disease-associated human TERT alleles give rise to a near-
normal telomerase enzyme activity, suggesting that these mutations
cause the disease by affecting telomerase functions that are not related
to its enzymatic activity (Zaug et al., 2013). These findings are in
apparent contradiction with those obtained in telomerase-deficient
mice, which exhibit defects in the haematopoietic system only when
telomeres are critically short (Lee et al., 1998). The most obvious
explanation is that there might be developmental and/or physiological
compensations in mice that probably do not exist in humans or fish.
Despite the concordance between findings in zebrafish and
studies of human clinical samples, it is important to highlight that
the zebrafish studies use MOs to downregulate the expression of
tert, terc and dkc1. Recently, the use of this technology has been
questioned throughout the zebrafish community. Unfortunately,
some morphant phenotypes have been proven to be due to off-target
effects, suggesting that it is always preferable to target exons
encoding domains that are necessary for protein function or
generating segmental deletions, rather than to use MOs (Kok
et al., 2015). Given the ease of use of current site-specific nuclease
technologies, most notably the CRISPR systems, it will be crucial to
generate new zebrafish lines, ideally carrying mutations similar to
those found in humans with DC, in order to confirm the importance
of the non-canonical functions of telomerase.
How do short telomeres drive aging?
As mentioned earlier, induced telomere shortening (in telomerase
mutants) is sufficient to cause a cascade of tissue dysfunctional
events in both high- and low-proliferation tissues. However, the
mechanistic basis underlying loss of homeostasis in the majority of
these tissues is still not understood. Deciphering whether these
mechanisms are also relevant in contexts of natural aging is crucial to
understand the impact of short telomeres in age-associated diseases.
Telomeres shortened to critical lengths become indistinguishable
from DNA double-strand breaks triggering DDRs (de Lange, 2005),
which results in the activation of p53 (d’Adda di Fagagna et al.,
2003; Gire et al., 2004; Guo et al., 2007). Accordingly, p53 acts
as a major executioner of short-telomere-induced defects in highly
proliferative tissues of both mice (Chin et al., 1999) and zebrafish
(Anchelin et al., 2013; Henriques et al., 2013). Deletion of p53 is
sufficient to prevent germ-cell apoptosis and infertility in late-
generation Terc−/−mice (Chin et al., 1999). However, this comes at
the high cost of increased genome instability and cancer (Artandi
et al., 2000; Chin et al., 1999; O’Hagan et al., 2002). Although p53
deficiency rescues premature death, cell-proliferation defects and
reduced gut-villi length of tert−/− zebrafish (Anchelin et al., 2013;
Henriques et al., 2013) (Table 1), its effect on tumour incidence
has not been described. Most likely, tert−/− tp53−/− zebrafish will
display an abnormally high incidence of cancer and early onset of
tumors, given that these features characterize the single tp53−/−
mutants [28% of fish develop malignant peripheral-nerve-sheath
tumors by 8 months (Berghmans et al., 2005)] and the single tert−/−
mutants (where cancer appears as early as 4 months) (Carneiro et al.,
2016). Alternatively, given that most tert−/− phenotypes related to
aging are suppressed in the absence of p53, it is also conceivable
that the onset of spontaneous tumours could be delayed in tert−/−
tp53−/− zebrafish.
Which molecular players act downstream of p53 to disrupt tissue
homeostasis in tert−/− zebrafish? A starting point to address this
question would be to investigate the molecular mechanisms already
described to mediate tissue dysfunction in late-generation
telomerase-knockout mice (Fig. 2), namely:
Type I: activation of the cell-cycle inhibitor p21 together with
p53-dependent modulator of apoptosis (PUMA). These
molecules are known to limit stem cell proliferation and the
regeneration capacities of high-turnover organs (e.g. intestine,
hematopoietic tissue) in G3/G4 Terc−/− mice (Choudhury et al.,
2007; Sperka et al., 2012).
Type II: repression of peroxisome proliferator-activated receptor
gamma coactivator 1-alpha/beta (PGC1α/β), master regulators of
mitochondrial biogenesis [possibly mediated by inhibition of
insulin-like growth factor 1 (IGF-1) and mammalian target
of rapamycin (mTOR) signalling]. Reduction of PGC1α/β lowers
oxidative defence mechanisms and gluconeogenesis, resulting in
an accumulation of ROS (Fig. 2). Altogether, these events have
been proposed to underlie dysfunction of more quiescent organs
(e.g. heart) in G3/G4 Terc−/−/Tert−/− mice (Missios et al., 2014;
Sahin et al., 2011).
Importantly, activation of type I or II mechanisms might not
be mutually exclusive; instead, these processes could occur
simultaneously within an individual tissue undergoing telomere
attrition. Because organs are composed of multiple cell types with a
wide spectrum of proliferative profiles, this raises the intriguing
question: which cells within a tissue undergoing telomere attrition
invoke which mechanism? What determines the choice?
There is already compelling evidence showing that stem cells with
short telomeres typically activate type I mechanisms, undergoing
growth arrest and apoptosis in the intestinal, skin, brain and
hematopoietic tissues (Choudhury et al., 2007; Ferrón et al., 2004;
Flores et al., 2005; Rajaraman et al., 2007; Sperka et al., 2012; Wong
et al., 2003). A recent study by Rudolph and colleagues further
demonstrated that this occurs only in stem cells that are actively
cycling (and not in those lying in a quiescent state), presumably to
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prevent transmission of aberrant genotoxic damage to progenitor cells
(Wang et al., 2014). We still do not know how cells other than adult
tissue stem cells deal with telomere-induced DDRs. Testing in vivo
how the expression of a given gene or pathway is affected in specific
telomere dysfunctional cells is a complex task. Zebrafish is an ideal
model for addressing these questions, given the possibility for live
visualization of the expression of different fluorescent reporters using
transparent telomere dysfunctional strains (specifically, albino strains).
Nevertheless, there are intrinsic limitations to the use of zebrafish – an
emerging model – in this area of research: it is a non-mammalian
system that either lacks specific cell markers or the reagents to detect
them. Furthermore, it remains to be shown whether key metabolic
processes in this cold-blooded animal are truly indistinguishable to
parallel processes in humans.
Telomerase, telomeres, senescence and tissue repair
Telomeres function as molecular clocks that keep a record of the
replicative history of primary cells (Harley et al., 1990). Telomere
erosion through consecutive cell divisions results in critically short
telomeres and elicits replicative senescence (Hayflick andMoorhead,
1961; Wang et al., 2014; Bodnar et al., 1998). Importantly, short
telomeres and senescent cells accumulate in some, but not in all,
tissues in aged humans (Dimri et al., 1995), monkeys (Herbig et al.,
2006) and mice (Wang et al., 2009). Since its initial description, our
understanding of cellular senescence has evolved dramatically and,
today, the concept of senescence has been redefined. In this section,
we discuss the importance of senescent cells in an organism, their
potential role in tissue regeneration and how this beneficial process
can be degraded, particularly in aged tissues.
In zebrafish, telomeres shorten during aging (Carneiro et al.,
2016; Anchelin et al., 2011) and upon loss of telomerase (tert−/−)
(Anchelin et al., 2013; Henriques et al., 2013). In both cases, the rate
of telomere decline varies between tissues (Carneiro et al., 2016).
As telomeres shorten, the number of senescent cells increases in the
skin (Kishi, 2004; Kishi et al., 2003), gut, testes and kidney marrow
(head kidney serves as the hematopoietic tissue in zebrafish)
(Carneiro et al., 2016). terf2 mutant embryos, which have
dysfunctional telomeres, also exhibit high levels of senescence-
associated β-galactosidase (SA-β-gal) activity, a widely used in
vitro marker for cellular senescence as well as of organismal aging
in vertebrates (Kishi et al., 2008). Moreover, the brains of old
zebrafish express high levels of smurf2, a gene implicated in the
induction of replicative senescence (Zhang and Cohen, 2004),
highlighting short telomeres as important triggers for cell
senescence in this teleost (Arslan-Ergul and Adams, 2014).
As telomeres get critically short, cellular senescence is activated,
and this leads to engagement of various signalling cascades that
ultimately activate p53, p16INK4a or both. In mammals, activated
p53 induces p21, causing a temporal cell-cycle arrest through the
inhibition of cyclin-E–Cdk2 (Beausejour et al., 2003). p16INK4a
also inhibits cell-cycle progression but does so by targeting cyclin-
D–Cdk4 and cyclin-D–Cdk6 complexes (Sherr and Roberts, 1999).
Both p21 and p16INK4a act by preventing CDK inactivation of Rb
(retinoblastoma protein), resulting in continued repression of E2F
target genes required for S-phase onset. The relative contribution of
p53, p21 or p16INK4a to the initial growth arrest can vary depending
on the type of stress. Their function, either alone or in combination,
could ultimately result in sustained senescence.
In zebrafish, the p53-p21 pathway is known to exist with relevant
functional conservation (Berghmans et al., 2005). As for the second
effector pathway, the human genetic locus that encodes for p16INK4a
also encodes for p15INK4b and a p53 stabilizer, known as p14ARF
(p19ARF in zebrafish). Despite the crucial role of the mammalian
INK4b-ARF-INK4a locus in tumour suppression, its counterpart
in zebrafish has not yet been fully characterized. Recently,
Sabaawy and colleagues identified one locus homologous to
human INK4 in zebrafish, which, surprisingly, was devoid of
ARF sequences (Sabaawy et al., 2006). This locus encodes a single
zebrafish ink4ab gene, which functions to activate senescence in
response to oxidative stress. Thus, zebrafish INK4ab seems to
function as a tumour suppressor similar to human p15INK4B and
p16INK4A (Davis and Sabaawy, 2013; Flaherty et al., 2015).
Although established senescence markers are lacking, most
senescent cells express the tumour suppressor p16INK4a (Ohtani
et al., 2004), the levels of which increase with age (Krishnamurthy
et al., 2004;Ressler et al., 2006). This rise of p16INK4a often coincides
with SA-β-gal activity (Dimri et al., 1995). Kishi and colleagues
reported SA-β-gal induction during aging in zebrafish (Kishi, 2004;
Kishi et al., 2003). His group has also been successful in exploiting
SA-β-gal staining as a marker for organismal senescence in zebrafish
larval models of premature aging (Kishi et al., 2008).
Curiously, senescent cells are still metabolically active and release
a complex mixture of extracellular matrix proteases, growth factors,
chemokines and cytokines [collectively known as senescence-
associated secretory phenotype (SASP)] that has significant effects
on the surrounding tissue microenvironment. SASP has not yet been
described in zebrafish; however, in mammals, it seems to have an
p53
Apoptosis
p21PUMA
Cell-cycle arrest
Senescence
PGC1α/β
ROS
Mitochondrial
dysfunction
Exogenous
damage 
(e.g. UV)
DNA-repair
deficiency
Telomere
dysfunction
Tissue dysfunction, aging and cancer
IGF-1?
Fig. 2. Pathways modulated by the short-telomere–p53 axis. Telomere
dysfunction, as well as exogenous genotoxic agents and deficiencies in DNA
repair, activates p53 (Chin et al., 1999), causing PUMA-mediated apoptosis
(Sperka et al., 2012) and p21 cell-cycle arrest, and, consequently, cell
senescence (Choudhury et al., 2007). p53 upregulation also leads to
impairments in energy homeostasis and potential suppression of IGF-1
signalling, which result in repression of master regulators (such as PGC1α/β) of
mitochondrial biogenesis. This leads to mitochondrial dysfunction and,
consequently, increased ROS levels, which promote further damage at
telomeres. ROS, reactive oxygen species. For further information and
references, see the main text.
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important role in recruiting immune and phagocytic cells, such as
macrophages, and also activates the motility and proliferation of
surrounding cells (Muñoz-Espín and Serrano, 2014).
Nowadays, senescence has been proposed as an alternative way of
cell death.While apoptosis is a rather individual and silent process of
cellular suicide, the senescent program requires the involvement
of different and complex players to bring about the same result: the
clearance of damaged cells (Muñoz-Espín and Serrano, 2014). Still,
the ultimate goal of senescence remains unclear. If in the end,
senescence is just another way to eliminate damaged cells then why
not choose a more direct and faster route of apoptosis?’ It has been
proposed that the central role of senescent cells is to initiate a tissue-
remodelling process that includes their own elimination. A
particularly striking example of the role of senescence in tissue
remodelling has been the recent demonstration that senescence
participates in developmental processes in vertebrates (Muñoz-Espín
et al., 2013; Storer et al., 2013), promotes wound healing in mice
(Demaria et al., 2014) and contributes to heart regeneration in
zebrafish (Bednarek et al., 2015).
Zebrafish has become a powerful model for investigating tissue
remodelling owing to its capacity to completely regenerate several
organ injuries, including brain, spinal cord, retina, heart and fins,
even at mature adult stages (Gemberling et al., 2013). This ability to
regenerate declines with age (Kishi et al., 2009) and, in some
organs, is heavily dependent on telomerase activity (Bednarek et al.,
2015; Elmore et al., 2008) (Fig. 3). Bednarek and colleagues have
recently shown that ventricular cryoinjury, a process that induces
massive cell death similar to that observed in a leading cause of
p53
p16p53
p16
3 dpi 60 dpi
Telomerase hyperactivation
Telomere elongation
Peak of proliferation
Senescence limited to the injury region
Impaired proliferation
Activation of DNA damage response
Accumulation of senescence beyond
  the injury region
Regeneration and
restoration of function
Fibrosis
Impaired ventricular 
  pumping efficacy
p53
p16?
SASP
SASP
SASP
Cryoinjury
Cryoinjury
?
?
?
?
?
Cryoinjury
Hyperactivation of
  telomerase
Proliferation
Senescence
DNA-damage response
Inflammatory response
Heart
A  Wild type 
B tert–/–
Key
Fig. 3. The role of telomerase, telomeres and senescent cells in zebrafish heart regeneration. Cryoinjury in zebrafish mimics aspects of human myocardial
infarction. (A) In wild-type fish, cardiomyocyte proliferation is sharply increased in response to tissue damage, accompanied by an increase in tert gene
expression, hyperactivation of telomerase and a transient elongation of telomeres (3 dpi). Additionally, there is an accumulation of senescence cells, limited to the
injured region (3 dpi) that is cleared upon wound closure (60 dpi) (Bednarek et al., 2015). Senescent cells release growth factors and cytokines, which might
activate the motility and proliferation of surrounding cells, potentiating tissue remodelling. (B) Aged cardiac tissues, modelled by the absence of telomerase
(tert−/−), are not amenable to tissue remodelling, reflecting a combination of factors, such as proliferative defects, accumulation of DNA-damaged cells and
increased senescence (3 dpi and 60 dpi). The difficulty in handling and clearing damaged and senescent cells might overload the tissue with the senescence-
associated secretory phenotype (SASP), which potentially contributes to a persistent chronic inflammatory microenvironment that further aggravates tissue
dysfunction and impairs proper wound closure (Bednarek et al., 2015).
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mortality and morbidity in humans – myocardial infarction – leads
to telomerase hyperactivation in cardiomyocytes, accompanied by a
sharp peak of proliferation and a transient elongation of telomeres
(Fig. 3A). Strikingly, SA-β-gal signalling was induced upon
cryoinjury, denoting an initial and transient accumulation of
senescent cells (Bednarek et al., 2015) (Fig. 3A). However,
senescence was limited to the injured region and easily cleared
upon wound closure. These observations are in line with studies in
mice (Demaria et al., 2014), supporting the hypothesis that, in an
in vivo context, cellular senescence might contribute to tissue
remodelling.
The full benefits of senescence are achieved when the process
includes the clearance of the senescent cells, thereby restoring the
pre-damage status of the tissue. However, in chronic pathological
situations such as aging (as modelled by tert−/− fish), cardiac
regeneration is impaired and a fibrotic scar remains. This inability to
regenerate is primarily due to a strong inhibition of the proliferative
response and an accumulation of senescent cells that becomes
persistent, and these cells even extend beyond the injured area,
further aggravating tissue dysfunction (Bednarek et al., 2015)
(Fig. 3B). The difficulty in handling and clearing damaged and
senescent cells could overload the tissue with SASP. This effect
results in a persistent chronic inflammatory microenvironment that
further aggravates tissue dysfunction and impairs proper
regeneration. This process might not be applicable to other types
of aged tissues, but constitutes a clear example of how short
telomeres and cellular senescence can contribute to age-related
defects in tissue regeneration.
Senescence is a double-edged sword, beneficial when it is
transient and easily handled but pathological when chronic and
unresolved. So, what makes an aged tissue more prone to the
accumulation of senescent cells? On the one hand, clearance of
senescent cells by the immune system might become impaired with
aging, leading to a net accumulation of senescent cells that further
aggravate tissue dysfunction via the SASP. On the other hand,
senescencemight not onlyaffect differentiated cells but also stemand
progenitor cells, thus limiting the regenerative capacity of tissues.
Modern society is extremely interested in finding ways to extend
human healthy lifespan. There are ongoing pharmacological tests
and biological therapies to prevent telomere shortening and
accumulation of senescent cells during aging. The impact this will
have on human health and disease is currently unknown, although it
will likely reveal new biological phenomena. If shortening of
telomeres can be prevented and/or senescent cells can be eliminated
in human tissues, will this simply delay the very familiar aging
phenomenon, or will new types of pathology emerge? These
nuances and complexities demand further investigation in order to
guide potential new therapeutic options.
Concluding remarks
Although telomere shortening is considered a primary culprit of
human aging, many questions remain unresolved. How do short
telomeres disrupt homeostasis in particular tissues over time?
Which precise molecular mechanisms mediate such tissue
dysfunction events in aging and premature-aging syndromes such
as DC? Addressing these issues has long been hampered by the lack
of a vertebrate laboratory model that recaps crucial human features,
including a 5-15 kb telomere length range and the immediate onset
of degenerative phenotypes upon removal of telomerase.
Ground-breaking discoveries establishing zebrafish as a powerful
model for the study of vertebrate telomeres have now filled this need.
Because zebrafish has human-like telomeres, deletion of telomerase
causes an acceleration of aging-associated diseases and tissue
dysfunction events that are observed in the first mutant generation
(Anchelin et al., 2013; Carneiro et al., 2016; Henriques et al., 2013).
These not only phenocopy what is observed in human aging, but also
reproduce the typical ‘anticipation phenomenon’ reported in humans
withDC (younger generations have an earlier disease onset) (Anchelin
et al., 2013; Henriques et al., 2013). Thus, phenotypes and molecular
mechanisms are both highly conserved from mammalian to zebrafish
in the context of telomere dysfunction, rendering this teleost a
promising model for telomere research in aging.
From testing the impact of telomerase therapeutics targeted to
specific tissues to identifying the molecular mechanisms that
mediate short-telomere-induced dysfunction in aging, several
challenges lie ahead in the field of telomere research using
zebrafish. The unique characteristics of this organism have
already proven useful for the identification of important new links
between tissue repair, telomerase activation and cellular senescence.
Defining how telomere dysfunction is interconnected to other
hallmarks of aging is bound to revolutionize the future of aging
therapeutics.
Competing interests
The authors declare no competing or financial interests.
Funding
This work was funded by the Portuguese Fundaça ̃o para a Ciência e Tecnologia
(FCT) (FCT) [PTDC/BIM-ONC/3402/2014] and Howard Hughes Medical Institute.
References
Aalfs, C. M., van den Berg, H., Barth, P. G. and Hennekam, R. C. M. (1995). The
Hoyeraal-Hreidarsson syndrome: the fourth case of a separate entity with prenatal
growth retardation, progressive pancytopenia and cerebellar hypoplasia.
Eur. J. Pediatr. 154, 304-308.
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